Editorial

DOI: 10.4244/EIJ-E-23-00062

Hybrid coronary revascularisation: the best or the worst of both worlds?

Mario Gaudino1, MD, PhD, MSCE; Sigrid Sandner2, MD, MSCE

In this issue of EuroIntervention, Dokollari et al1 report the outcomes of 2,280 patients who underwent robotic-assisted coronary artery bypass grafting (CABG) procedures between 2005 and 2021, of which 868 (38%) were performed as hybrid coronary revascularisation (HCR) procedures. These procedures consisted of robotic-assisted left internal thoracic artery (LITA)-to-left anterior descending (LAD) CABG via a left thoracotomy and subsequent percutaneous coronary intervention (PCI) of non-LAD target vessels. The authors analysed outcomes over three 5-year periods during which the proportion of HCR procedures increased substantially, rising from 25.5% between 2005 and 2010 to 48.4% between 2017 and 2021.

This analysis draws on the extensive experience of a dedicated centre for robotic coronary surgery. Despite an increasing burden of patient comorbidities, perioperative and postoperative outcomes improved significantly over the course of the study period, highlighting the fact that robotic-assisted, minimally invasive CABG is a complex operation that is associated with a considerable learning curve.

Appropriately, the authors reserved HCR for patients deemed unsuitable for conventional CABG by the local Heart Team. However, in the last years of their study, this proportion of patients was much higher than is generally reported by other centres, indicating a bias toward HCR in this particular centre.

Beyond this niche experience from a dedicated centre for robotic coronary surgery, the role of HCR in current practice remains largely unclear. Intuitively, HCR only makes sense if the surgical portion is performed using sternal-sparing approaches. The minimally invasive LITA-LAD CABG is a technically complex operation that is difficult to standardise and perform on a routine basis. The National Heart, Lung, and Blood Institute-sponsored, randomised Hybrid Trial (Hybrid Coronary Revascularization Trial)2, designed to investigate whether HCR was superior to multivessel PCI, ended prematurely because of low enrolment due to a lack of expertise and confidence with minimally invasive CABG techniques in the surgical community. Given the described volume-to-outcome relationship, HCR as a routine procedure would need to be performed in dedicated centres that are already experienced in minimally invasive CABG, which would lead to obvious logistical and access issues.

Does HCR, as the authors write, offer “the best of both worlds” to all CABG patients? We think not. Surgical CABG grafts are placed several centimetres distal to the stenosis, thereby protecting not only against flow-limiting plaque but also against the progression of other proximal lesions that are non-flow limiting at the time of surgery. This “surgical collateralisation” is the postulated mechanism for the reduction in spontaneous myocardial infarction and mortality seen in some clinical trials comparing CABG with PCI, which only treats the flow-limiting lesions3. This benefit of CABG is obviously lost with HCR, where a surgical collateral is only built in the LAD territory. If we were to regard non-LAD target vessels as irrelevant to outcomes in patients with complex multivessel disease, the current evidence of clinical benefits when using conduits with better patency rates for non-LAD targets would be difficult to explain45. On the other hand, if it is a quick recovery from the procedure and an improved short-term quality of life that are important to the patient, then HCR obviously cannot compete with multivessel PCI.

As randomised evidence is lacking, the role of HCR beyond carefully selected patient subgroups remains to be determined, and therefore, the technique should currently be regarded as a niche area of clinical research rather than part of clinical practice.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 20 Number 1
Jan 1, 2024
Volume 20 Number 1
View full issue


Key metrics

On the same subject

Original Research

10.4244/EIJ-D-23-00373 Jan 1, 2024
Long-term clinical outcomes of robotic-assisted surgical coronary artery revascularisation
Dokollari A et al

10.4244/EIJV14I4A69 Jul 20, 2018
What is new in the armamentarium of coronary surgeons to compete with PCI?
Gaudino M and Taggart D
free

Original Research

10.4244/EIJ-D-23-00375 Jan 1, 2024
Procedural and one-year outcomes of robotic-assisted versus manual percutaneous coronary intervention
Bay B et al

Clinical research

10.4244/EIJ-D-19-00463 Dec 6, 2019
Graft patency after FFR-guided versus angiography-guided coronary artery bypass grafting: the GRAFFITI trial
Toth GG et al
free

10.4244/EIJV15I17A269 Apr 17, 2020
Major infections after bypass surgery and stenting: an overlooked but fatal complication
Harari R and Bangalore S
free

10.4244/EIJV13I5A94 Aug 4, 2017
EXCEL and NOBLE: stents or surgery for left main stem stenosis?
Mangiacapra F et al
free
Trending articles
187.45

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
170.15

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
159.45

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
127.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
108.75

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved